Apr 24, 2017 11:01 am UTC| Business
- Microbiology analysis and full results of Phase 3 OASIS study presented at ECCMID 2017 - Data on utility in geographic regions also presented VIENNA, Austria, April 24, 2017 -- Paratek Pharmaceuticals, Inc....
Apr 24, 2017 11:01 am UTC| Business
- Microbiology analysis and full results of Phase 3 OASIS study presented at ECCMID 2017 - Data on utility in geographic regions also presented VIENNA, Austria, April 24, 2017 -- Paratek Pharmaceuticals, Inc....
Capital City Bank Group, Inc. Reports First Quarter 2017 Results
Apr 24, 2017 11:01 am UTC| Business
TALLAHASSEE, Fla., April 24, 2017 -- Capital City Bank Group, Inc. (Nasdaq:CCBG) today reported net income of $2.7 million, or $0.16 per diluted share for the first quarter of 2017 compared to net income of $3.3...
Capital City Bank Group, Inc. Reports First Quarter 2017 Results
Apr 24, 2017 11:01 am UTC| Business
TALLAHASSEE, Fla., April 24, 2017 -- Capital City Bank Group, Inc. (Nasdaq:CCBG) today reported net income of $2.7 million, or $0.16 per diluted share for the first quarter of 2017 compared to net income of $3.3...
Apr 24, 2017 11:01 am UTC| Business
VIENNA, Austria, April 24, 2017 -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that two cost benefit analyses presented at the annual meeting of the European Congress of Clinical Microbiology and...
Apr 24, 2017 11:01 am UTC| Business
VIENNA, Austria, April 24, 2017 -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that two cost benefit analyses presented at the annual meeting of the European Congress of Clinical Microbiology and...
Apr 24, 2017 11:00 am UTC| Business
STAMFORD, Conn., April 24, 2017 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by...